• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sean Whooley

Vaxxas receives more than $5 million grant for vaccine delivery patch

September 20, 2022 By Sean Whooley

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Vaxxas

Study says Abbott FreeStyle Libre reduces rate of hospitalization

September 20, 2022 By Sean Whooley

Abbott FreeStyle Libre CGM

Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily […]

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring Tagged With: abbott

Insulet wins CE Mark for Omnipod 5 for children 2 and up

September 20, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6

Insulet (Nasdaq:PODD) announced today that it received CE mark approval in Europe for its Omnipod 5 automated insulin delivery system. Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, Massachusetts-based Insulet said it represents the first CE-marked tubeless hybrid closed loop system. The latest-generation Omnipod 5 […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance Tagged With: Dexcom, Insulet

Advanced NanoTherapies wins FDA breakthrough nod for drug-coated balloon

September 19, 2022 By Sean Whooley

Advanced NanoTherapies Sirplux Duo

Advanced NanoTherapies announced today that it received FDA breakthrough device designation for its SirPlux Duo drug-coated balloon (DCB). Los Gatos, California-based Advanced NanoTherapies received the breakthrough nod for the use of the DCB in treating coronary artery disease in vessels less than 3.0mm. The regulatory win comes weeks after two previous breakthrough designations. SirPlux Duo […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Advanced NanoTherapies, FDA

Recall of Baxter Clearlink due to risk of leaks is Class I

September 15, 2022 By Sean Whooley

Baxter logo

The FDA announced today that the recall of the Clearlink basic solution set with Duovent from Baxter (NYSE:BAX) is Class I, the most serious kind. Clearkink with Duovent is part of a system for administering drugs and solutions to patients. Health providers use the majority of the sets to deliver hazardous drugs, such as chemotherapy […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: Baxter, FDA

Philip Morris hires two former FDA officials as it pushes ‘smoke-free’ development

September 14, 2022 By Sean Whooley

Philip Morris Logo

Cigarette maker Philip Morris (NYSE:PM) announced today that it appointed two former FDA officials to leadership positions. Dr. Badrul Chowdhury is the company’s new chief life sciences officer for smoke-free products. Dr. Matthew Holman joins as VP of U.S. scientific engagement and regulatory strategy. Both appointments fall in line with the company’s efforts to push […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Respiratory Tagged With: FDA, Personnel, Personnel Moves, Philip Morris

Turn Biotechnologies launches delivery system for nucleic acid therapeutics

September 13, 2022 By Sean Whooley

Turn Biotechnologies

Turn Biotechnologies announced today that it created a novel platform for the safe and effective delivery of nucleic acid therapeutics. Mountain View, California-based Turn said in a news release that the platform represents a “major expansion” of its business. It designed its eTurna Platform for the next generation of precision medicine. eTurna allows for fine-tuning […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals Tagged With: Turn Biotechnologies

BD launches next-gen prefillable vaccine syringe

September 13, 2022 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) announced today that it launched its next-generation glass prefillable syringe (PFS) for vaccine delivery. Franklin Lakes, New Jersey-based BD’s new Effivax syringe features tightened specifications for processability, cosmetics, contamination and integrity. The company designed it in collaboration with top pharmaceutical firms to meet the evolving needs of vaccine manufacturing. “As biopharmaceutical companies continue […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD

FDA clears embolic microspheres from ABK Biomedical

September 12, 2022 By Sean Whooley

ABK Biomedical Logo

ABK Biomedical announced today that it received FDA 510(k) clearance for its Easi-Vue embolic microspheres for treating tumors. Halifax, Nova Scotia-based ABK designed its microspheres for treating patients with arteriovenous malformations and hypervascular tumors. Vascular embolization is an effective therapy for addressing symptoms of these conditions. ABK said in a news release that microsphere embolization […]

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Radiosurgery, Regulatory/Compliance Tagged With: ABK Biomedical

MedAlliance enrolls first patient in study of drug-eluting balloon for treating erectile dysfunction

September 9, 2022 By Sean Whooley

MedAlliance SELUTION SLR

MedAlliance announced today that it enrolled the first patient in a trial for its drug-eluting ballon in treating erectile dysfunction. Geneva, Switzerland-based MedAlliance said an 82-year-old Taiwanese man enrolled in the initial trial. It will evaluate the Selution SLR sirolimus-eluting balloon for the treatment of erectile dysfunction (ED). The Perfect-Selution FIM study includes 54 patients. […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: MedAlliance

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 132
  • Page 133
  • Page 134
  • Page 135
  • Page 136
  • Interim pages omitted …
  • Page 217
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS